Sanofi, Re­gen­eron gear up for new Dupix­ent fil­ing af­ter clear­ing sec­ond PhI­II for eosinophilic esophagi­tis

This fall’s har­vest is prov­ing fruit­ful for Dupix­ent.

Days af­ter tout­ing a clean Phase III sweep in pruri­go nodu­laris, Sanofi and Re­gen­eron re­port that their block­buster an­ti-in­flam­ma­to­ry drug has passed an­oth­er Phase III test with fly­ing col­ors, paving the way for reg­u­la­to­ry fil­ings in 2022.

It’s the sec­ond tri­al where Dupix­ent has proven ef­fec­tive against eosinophilic esophagi­tis, meet­ing the co-pri­ma­ry end­points by spurring sig­nif­i­cant im­prove­ments in both clin­i­cal and his­to­log­ic dis­ease mea­sures.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER